Entheon Biomedical

April 10, 2021

Entheon Biomedical commercializes industry’s first psychedelics genetic test kit

As pioneers of a leading-edge addiction recovery solution based on psychedelic medicine, Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) has been actively expanding its business over the past weeks. The culmination of that work is the release of a potentially groundbreaking product in the field of psychedelic therapy, which would also represent the company’s first revenue stream.
February 18, 2021

Entheon Biomedical: Psychedelic-assisted therapy presents a new pathway to solving Canada’s opioid crisis

2021.02.18 Despite improvements in medical technology and billions of dollars injected into treatment […]
January 16, 2021
man holding head pills

Entheon Biomedical makes investment in psychiatric clinic platform

2021.01.16 Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) has completed its first deal […]
December 2, 2020

Entheon Biomedical hires Dutch research firm to conduct human clinical trial of psychedelic drug DMT

2020.12.02 Opioids belong to a class of medications used to treat pain. Examples […]
November 28, 2020

Entheon Biomedical: Opioid addiction – a history

2020.11.28 Opioids belong to a class of medications used to treat pain. Examples […]
November 12, 2020
pharma crisis opiod

Entheon Biomedical (CSE:ENBI): Developing a powerful psychedelic-assisted therapy for the treatment of addiction

2020.11.12 Psychedelic drugs, or sometimes called hallucinogens, are shrouded in a mist of […]